Cargando…

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides

Development of potent and broad-spectrum antivirals against SARS-CoV-2 remains one of top priorities, especially in the case of that current vaccines cannot effectively prevent viral transmission. We previously generated a group of fusion-inhibitory lipopeptides, with one formulation being evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yue, Zhu, Yuanmei, Yu, Yanying, Liu, Nian, Ju, Xiaohui, Ding, Qiang, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977133/ https://www.ncbi.nlm.nih.gov/pubmed/36868315 http://dx.doi.org/10.1016/j.antiviral.2023.105571

Ejemplares similares

Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2023)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors
por: Liu, I-Jung, et al.
Publicado: (2009)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains
por: Xia, Shuai, et al.
Publicado: (2018)

Targeting the SARS-CoV-2 HR1 with Small Molecules as Inhibitors of the Fusion Process
por: Gentile, Davide, et al.
Publicado: (2022)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif
por: Wu, Tong, et al.
Publicado: (2022)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2
por: Zhu, Yuanmei, et al.
Publicado: (2023)

HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
por: Lu, Ying, et al.
Publicado: (2023)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Impact of the HIV-1 env Genetic Context outside HR1–HR2 on Resistance to the Fusion Inhibitor Enfuvirtide and Viral Infectivity in Clinical Isolates
por: Baatz, Franky, et al.
Publicado: (2011)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Molecular determinants for regulation of G3BP1/2 phase separation by the SARS-CoV-2 nucleocapsid protein
por: Huang, Wenjie, et al.
Publicado: (2021)

Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry
por: Mzoughi, Olfa, et al.
Publicado: (2019)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
por: Chen, Yue, et al.
Publicado: (2021)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Design of HR1 and HR2 synthetic peptide analogs: Characterization of their antiviral activities and their capacities to induce neutralizing antibodies
por: Mzoughi, Olfa, et al.
Publicado: (2013)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2022)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

A tissue specific-infection mouse model of SARS-CoV-2
por: Yang, Bo, et al.
Publicado: (2023)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein
por: Hu, Xin, et al.
Publicado: (2021)

The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner
por: Lai, Alex L., et al.
Publicado: (2017)

The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner
por: Lai, Alex L., et al.
Publicado: (2019)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Postprandial 2-hr C-peptide Concentration as a Guide for Insulin Treatment in Patient with NIDDM
por: Kim, Rhee Sook, et al.
Publicado: (1986)

SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense
por: Ju, Xiaohui, et al.
Publicado: (2023)

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor
por: Chong, Huihui, et al.
Publicado: (2012)

The hr1 and Fusion Peptide Regions of the Subgroup B Avian Sarcoma and Leukosis Virus Envelope Glycoprotein Influence Low pH-Dependent Membrane Fusion
por: Babel, Angeline Rose, et al.
Publicado: (2007)

Peptide and peptide-based inhibitors of SARS-CoV-2 entry
por: Schütz, Desiree, et al.
Publicado: (2020)

Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
por: Elshabrawy, Hatem A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r5f2l3hf6g2v6r3mu4gh1hvd8c